Literature DB >> 12678775

Development and application of bioprobes for Mammalian cell cycle analyses.

Hiroyuki Osada1.   

Abstract

In this review, I have mainly described the cell cycle inhibitors isolated from microbial metabolites. Once the molecular target of the inhibitor is determined, the inhibitor can be used as bioprobe to dissect the diverse aspect of biological functions in chemical biology research. Reveromycin A and phosmidosine inhibited the protein synthesis of mammalian cells and arrested the cell cycle at G1 phase. Lucilactaene arrested cells at G1 phase through restoration of mutant p53. Tryprostatin A inhibited the microtubule polymerization by interfering with the interaction between tubulin and microtubule associating protein. On the contrary, cyclotryprostatin D, structurally related to tryprostatin A, enhanced the tubulin polymerization. Terpendole E inhibited the motor activity of mitotic kinesin, Eg5 and induced monoastral spindle in M phase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12678775     DOI: 10.2174/0929867033457836

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  3 in total

1.  Terminating Catalytic Asymmetric Heck Cyclizations by Stereoselective Intramolecular Capture of η-Allylpalladium Intermediates: Total Synthesis of (-)-Spirotryprostatin B and Three Stereoisomers.

Authors:  Larry E Overman; Mark D Rosen
Journal:  Tetrahedron       Date:  2010-08-14       Impact factor: 2.457

Review 2.  Chemical and biological studies of reveromycin A.

Authors:  Hiroyuki Osada
Journal:  J Antibiot (Tokyo)       Date:  2016-06-08       Impact factor: 2.649

3.  Proteomic profiling reveals that collismycin A is an iron chelator.

Authors:  Makoto Kawatani; Makoto Muroi; Akira Wada; Gyo Inoue; Yushi Futamura; Harumi Aono; Kenshirou Shimizu; Takeshi Shimizu; Yasuhiro Igarashi; Naoko Takahashi-Ando; Hiroyuki Osada
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.